Similar articles for PMID: 27492073

Year	Number of Results
2008	1
2009	3
2010	7
2011	5
2012	6
2013	7
2014	7
2015	8
2016	17
2017	17
2018	18
2019	20
2020	12
2021	2
2022	8
2023	4
2024	0

1

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS. Nguyen HS, et al. AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. doi: 10.3174/ajnr.A4898. Epub 2016 Aug 4. AJNR Am J Neuroradiol. 2016. PMID: 27492073 Free PMC article.

2

Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.

Auer TA, Breit HC, Marini F, Renovanz M, Ringel F, Sommer CJ, Brockmann MA, Tanyildizi Y. Auer TA, et al. J Neuroradiol. 2019 Feb;46(1):36-43. doi: 10.1016/j.neurad.2018.04.002. Epub 2018 May 4. J Neuroradiol. 2019. PMID: 29733920

3

Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.

Galla N, Chiang G, Chakraborty S, Singh R, John Tsiouris A, Boockvar J, Kovanlikaya I. Galla N, et al. Neuroradiology. 2017 May;59(5):499-505. doi: 10.1007/s00234-017-1820-4. Epub 2017 Mar 25. Neuroradiology. 2017. PMID: 28343250

4

Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF. Ellingson BM, et al. AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9. doi: 10.3174/ajnr.A3748. Epub 2013 Oct 17. AJNR Am J Neuroradiol. 2014. PMID: 24136647 Free PMC article.

5

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Ellingson BM, et al. Neuro Oncol. 2011 Oct;13(10):1151-61. doi: 10.1093/neuonc/nor079. Epub 2011 Aug 19. Neuro Oncol. 2011. PMID: 21856685 Free PMC article.

6

Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.

Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Patel KS, et al. Neurosurgery. 2020 Oct 15;87(5):931-938. doi: 10.1093/neuros/nyaa135. Neurosurgery. 2020. PMID: 32365185 Free PMC article.

7

Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.

Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ. Zhang M, et al. Neuro Oncol. 2016 May;18(5):735-43. doi: 10.1093/neuonc/nov268. Epub 2015 Nov 3. Neuro Oncol. 2016. PMID: 26538618 Free PMC article.

8

Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.

Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A. Buemi F, et al. Neuroradiol J. 2019 Aug;32(4):241-249. doi: 10.1177/1971400919847184. Epub 2019 May 8. Neuroradiol J. 2019. PMID: 31066622 Free PMC article.

9

Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Zakhari N, Taccone MS, Torres C, Chakraborty S, Sinclair J, Woulfe J, Jansen GH, Nguyen TB. Zakhari N, et al. AJNR Am J Neuroradiol. 2018 Feb;39(2):260-264. doi: 10.3174/ajnr.A5485. Epub 2017 Dec 7. AJNR Am J Neuroradiol. 2018. PMID: 29217742 Free PMC article.

10

Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.

Toh CH, Liau CT, Wei KC, Castillo M. Toh CH, et al. J Neurooncol. 2019 Mar;142(1):149-159. doi: 10.1007/s11060-018-03075-x. Epub 2018 Dec 10. J Neurooncol. 2019. PMID: 30535596

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year